

Claims

1. A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof.
2. A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1, 2, 28, 29, 30, 31, 32, 51, 52, 60 and 61 or a fragment thereof.
3. A composition for diagnosing or treating lung cancer comprising the protein or fragment thereof according to Claim 2.
4. A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 53, 54 and 55 or a fragment thereof.
5. A composition for diagnosing or treating stomach cancer comprising the protein or fragment thereof according to Claim 4.
6. A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 3, 7, 20, 21, 46, 47, 48, 49 and 50 or a fragment thereof.
7. A composition for diagnosing or treating large bowel cancer comprising the protein or fragment thereof according to Claim 6.
8. A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 14, 15, 16, 17, 18, 19, 43, 44, 45, 56, 57, 58, 59, 62, 63, 64 and 65 or a fragment thereof.
9. A composition for diagnosing or treating liver cancer comprising the protein or fragment thereof according to Claim 8.
10. The protein or fragment thereof according to Claim 1, wherein the gene has a nucleotide sequence represented by any of SEQ ID NOs:

1, 9, 10, 14, 20, 22, 24, 25, 26, 27, 28, 29, 32, 38, 39, 40, 44, 51, 52, 53, 54 and 58.

11. The protein or fragment thereof according to Claim 1, wherein the gene has a nucleotide sequence represented by any of SEQ ID NOs: 1, 9, 10, 14, 20, 22, 24, 25 and 26.

12. The protein or fragment thereof according to Claim 1, having an amino acid sequence represented by any of SEQ ID NOs: 66 to 123.

13. An antibody recognizing the protein or fragment thereof according to any one of Claims 1, 2, 4, 6, 8, 10, 11 and 12.

14. A polynucleotide having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto, and a polynucleotide hybridizing under high stringent conditions to any of said polynucleotides.

15. A polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto, and a polynucleotide having at least 12 nucleotides hybridizing under high stringent conditions to any of said polynucleotides.

16. The polynucleotide according to Claim 14 or 15, having a nucleotide sequence represented by any of SEQ ID NOs: 1, 2, 28, 29, 30, 31, 32, 51, 52, 60 and 61.

17. A composition for diagnosing or treating lung cancer comprising the polynucleotide according to Claim 16.

18. The polynucleotide according to Claim 14 or 15, having a nucleotide sequence represented by any of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 53, 54 and 55.

19. A composition for diagnosing or treating stomach cancer comprising the polynucleotide according to Claim 18.
20. The polynucleotide according to Claim 14 or 15, having a nucleotide sequence represented by any of SEQ ID NOs: 3, 7, 20, 21, 46, 47, 48, 49 and 50.
21. A composition for diagnosing or treating large bowel cancer comprising the polynucleotide according to Claim 20.
22. The polynucleotide according to Claim 14 or 15, having a nucleotide sequence represented by any of SEQ ID NOs: 14, 15, 16, 17, 18, 19, 43, 44, 45, 56, 57, 58, 59, 62, 63, 64 and 65.
23. A composition for diagnosing or treating lung cancer comprising the polynucleotide according to Claim 22.
24. The polynucleotide according to Claim 14 or 15, having a nucleotide sequence represented by any of SEQ ID NOs: 1, 9, 10, 14, 20, 22, 24, 25, 26, 27, 28, 29, 32, 38, 39, 40, 44, 51, 52, 53, 54 and 58.
25. A vector comprising the polynucleotide according to any one of Claims 14, 15, 16, 18, 20, 22 and 24.
26. A cell comprising the vector according to Claim 25.
27. A method of identifying a compound having an anticancer activity comprising the steps of:
- bringing a cultured human cell into contact with a test compound;
 - and
 - identifying a compound that causes a change in the expression level of a gene containing a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 in the cell as a compound having an anticancer activity.

28. A method of diagnosing cancer comprising measuring the expression level of the protein according to any one of Claims 1, 2, 4, 6, 8, 10, 11 and 12 or the polynucleotide according to any one of Claims 14, 15, 16, 18, 20, 22 and 24.
29. A method of diagnosing cancer comprising detecting C20orf102 protein.
30. The method according to Claim 29, wherein the cancer is lung cancer, liver cancer or pancreatic cancer.
31. The method according to Claim 29, wherein a secretory form of C20orf102 protein is detected.
32. The method according to Claim 29 wherein C20orf102 protein is detected by an antibody recognizing C20orf102 protein.
33. The method according to Claim 29, wherein C20orf102 protein present in blood, serum or plasma is detected.
34. A method of diagnosing cancer comprising the steps of:
- (a) collecting a sample from a subject; and
 - (b) detecting C20orf102 protein contained in the collected sample.
35. The method according to Claim 34, wherein the sample collected from the subject is blood, serum or plasma.
36. The method according to Claim 34, wherein an extracellular domain of C20orf102 protein is detected.
37. The diagnostic method according to Claim 34, wherein C20orf102 protein is detected by an antibody recognizing C20orf102 protein.